TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential. The previous Phase 1b trial of TTP273 demonstrated robust effects on postprandial and fasting glucose. All doses
Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation. In order to qualify for orphan drug designation with
Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein being developed by AbbVie in partnership with Genentech and Roche. The designation is supported by an investigational study
A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected
The purpose of the proposed Joint Venture is to produce Neovacs’ Kinoid product candidates, including IFNa-Kinoid, as well as potentially manufacture other KLH-based immunotherapies on behalf of third
The company’s latest report states that the increase in PAH treatment sales, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the
EyeGate president and CEO Stephen From said: "Enrolling the first patient in our second Phase 3 trial for anterior uveitis marks an important milestone for the company as
This Phase 2B study, is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients
Designed to validate Immunovia´s blood test, IMMray PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half
In a previously reported Phase 1a study of the safety of 4 weekly doses of AZD1419 compared to placebo in 45 healthy volunteers, ascending doses were well tolerated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.